Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer
A Phase Ⅱ Study Evaluate the Efficacy and Safety of LY01610（Irinotecan Hydrochloride Liposome Injection） in Patients With Small Cell Lung Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The objectives are to evaluate the efficacy and safety of LY01610 in subjects with extensive small cell lung cancer that progressed after first-line antitumor therapy.
Patients were enrolled in one to three cohorts to receive LY01610 every 2 weeks, initial 30 subjects will be included in each cohort and the number of the cases could be adjusted. Subjects will receive LY01610 start with 60 mg/m2 every 2 weeks，when the sixth subjects of the current cohort completed 14 days safety observation of the first LY01610 administration, the investigators will evaluate the ongoing dose tolerance. If the investigator and the sponsor jointly believe that other doses can provide greater potential benefits for patients while ensuring safety and benefit, other appropriate cohorts could be explored (such as 80, 90 and 100 mg/m2, etc.) Subjects will receive the LY01610 monotherapy until occurrence of progressive disease (PD), death, intolerable toxicity reaction, withdrawal of informed consent, conduct of other antitumor therapy or completion of the whole study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Beijing
-
Peking, Beijing, China, 100021
- Chinese Academy of Medical Sciences and Peking Union Medical College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
1.Male or female patients aged 18 to 70 years (18 years and 70 years are inclusive).
2.Histologically or cytologically confirmed extensive small cell lung cancer. 3.Disease progression or recurrence after one prior systematic anti-tumor treatment regimen (including platinum-containing chemotherapy, etc.; with or without radiotherapy).
4.The patient should have at least one measurable lesion (according to RECIST 1.1 criteria).
5.Life expectancy ≥3 months. 6.The Eastern Cooperative Oncology Group (ECOG) performance status score is between 0 to 1 point.
7.Laboratory results during screening:
- Hematology：Absolute neutrophil count ≥ 1.5× 109/L, platelet count≥ 100× 109/L and hemoglobin≥ 90 g/L.
- Liver function: Total bilirubin <1.5×upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN for the subjects without liver metastasis; ALT and AST≤5×ULN for the subjects with liver metastasis.
- Kidney function: Serum creatinine ≤ 1.5 ×ULN or creatinine clearance rate ≥ 50 mL/min.
Coagulative function: Prothrombin time - international standardized ratio（PT-INR） <1.5.
8.The subject has voluntarily signed the written informed consent form (ICF) and can comply with the study protocol.
9.The female subjects and male subjects of childbearing age and the partners of the male subjects agree to take reliable contraceptive measures (such as abstinence, sterilizing operation, contraceptives, injection of the contraceptive drug medroxyprogesterone acetate or subdermal implant of contraceptives) during the study period and within 6 months after infusion of the study drugs.
Exclusion Criteria:
1.Patients with the symptomatic brain metastasis, meningeal metastases, spinal cord tumor invasion, spinal cord compression. Patients with superior vena cava syndrome, obstructive atelectasis and bone metastasis who have local symptoms, which may require radiotherapy / surgery / endoscopic treatment / interventional treatment and other non-medical treatment.
2.Patients have other malignant tumors within 5 years(except for cured stage ⅠB or lower cervical cancer, non-invasive basal cell or squamous cell skin cancer) 3.Uncontrolled massive hydrothorax, ascites and pericardial effusion. 4.Patients have history of deep vein thrombosis or pulmonary embolism. 5.The patient with persistent or active infection signs which need intravenous injection of antibiotics.
6.Medical history of the following diseases within 6 months: myocardial infarction, unstable angina pectoris, coronary revascularization, cardiac dysfunction (New York heart association (NYHA) grade ≥ II), severe unstable ventricular arrhythmia or arrhythmias that need to be treated at the time of screening.
7.The patient with Active hepatitis B: hepatitis B surface antigen (HBsAg) positive and the peripheral blood hepatitis B virus DNA (HBV DNA)titer ≥1× 103 copies/mL or 200 IU/ml. The subject is eligible to be enrolled if HBsAg is positive and peripheral blood HBV DNA titer <1×103 copies/mL or 200 IU/ml and the investigator considers that the subject is at the stable stage of chronic hepatitis and the risk will not be increased for the subject. The patient with hepatitis C virus (HCV) antibody positive, human immunodeficiency virus (HIV) antibody positive and active syphilis infection.
8.Patients have severe gastrointestinal disorders (such as gastrointestinal bleeding, infection, chronic enteritis, obstruction, or diarrhea with CTCAE grade 1 or higher) at the time of screening.
9.Patients with medical history of neuropathy or mental disorder (including epilepsy or dementia).
10.Patients have been or are suffering from bronchial asthma, interstitial lung disease or active hemoptysis within 6 months.
11.Patients with primary diseases of other major organs (such as nervous system, cardiovascular system, urinary system, digestive system, respiratory system or metabolic endocrine system) and the investigators believe that it is not suitable for enrollment, or for other reasons the investigators don't think that suitable for inclusion.
12.Patients who have previous treatment with irinotecan or immunotherapy. 13.Known hypersensitivity to any of the components of irinotecan liposome injection, other structurally similar compounds (such as camptothecins), or other liposomal products.
14.Patients have participated in other pharmaceutical clinical trial within one month before screening.
15.Patients have received systemic antitumor therapy such as radiation, chemotherapy, immunotherapy or other treatments within 4 weeks prior to start of therapy.
16.Patients have received live or attenuated vaccines within one month prior to the screening.
17.Use of strong CYP3A4 inducers (phenytoin or carbamazepine, barbiturates, rifampin, rifabutin or rifapentine, hypericum perforatum, etc) during or within 14 days prior to starting study medication.
18.Use of strong CYP3A4 inhibitors (clarithromycin, ketoconazole or itraconazole, indinavir, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir,voriconazole, etc) during or within 14 days prior to starting study medication. 19.Use of strong UGT1A1 inhibitors during or within 14 days prior to starting study medication (atazanavir, gemfibrozil, indinavir, etc.).
20.Patients who are taking or may take drugs that reduce cholinesterase activity or choline drugs (neostigmine, lissamine, acetylcholine, etc.).
21.Patients may used the skeletal muscle relaxation drugs (such as succinylcholine) during the trial.
22.The patient who has drug and/or alcohol abuse. 23.Pregnant or lactating women. 24.Patients who did not take contraceptive measures during the trial. 25.Other circumstances which are considered by the investigator that the subject is unsuitable to be enrolled.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: LY01610
LY01610(Irinotecan Hydrochloride Liposome Injection),Patients were enrolled in one to three cohorts to receive LY01610 every 2 weeks, initial 30 subjects will be included in each cohort and the number of the cases could be adjusted.
Subjects will receive LY01610 start with 60 mg/m2 every 2 weeks，when the sixth subjects of the current cohort completed 14 days safety observation of the first LY01610 administration, the investigators will evaluate the ongoing dose tolerance.
If the investigator and the sponsor jointly believe that other doses can provide greater potential benefits for patients while ensuring safety and benefit, other appropriate cohorts could be explored (such as 80, 90 and 100 mg/m2, etc.) Subjects will receive the LY01610 monotherapy until occurrence of progressive disease (PD), death, intolerable toxicity reaction, withdrawal of informed consent, conduct of other antitumor therapy or completion of the whole study.
|
LY01610 will be administered via intravenous infusion every 2 weeks on Day 1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Objective Response Rate(ORR)
Time Frame: from the date of randomisation to the date of disease progression or death up to 12 months from randomisation of the last subject
|
from the date of randomisation to the date of disease progression or death up to 12 months from randomisation of the last subject
|
|
Duration of Response(DoR)
Time Frame: from the date of randomisation to the date of disease progression or death up to 12 months from randomisation of the last subject
|
from the date of randomisation to the date of disease progression or death up to 12 months from randomisation of the last subject
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Disease Control Rate(DCR)
Time Frame: from the date of randomisation to the date of disease progression or death up to 12 months from randomisation of the last subject
|
from the date of randomisation to the date of disease progression or death up to 12 months from randomisation of the last subject
|
|
Progression Free Survival(PFS)
Time Frame: from the date of randomisation to the date of disease progression or death up to 12 months from randomisation of the last subject
|
from the date of randomisation to the date of disease progression or death up to 12 months from randomisation of the last subject
|
|
Overall Survival(OS)
Time Frame: from the date of randomisation to the date of death up to 12 months from randomisation of the last subject
|
from the date of randomisation to the date of death up to 12 months from randomisation of the last subject
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yuankai Shi, Professor, Chinese Academy of Medical Sciences and Peking Union Medical College
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Small Cell Lung Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Irinotecan
Other Study ID Numbers
- LY01610/CT-CHN-202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.